Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. develops engineered T cell therapies for autoimmune diseases as a late-stage clinical biotechnology company. Its CABA platform includes the CARTA strategy, and its lead investigational therapy, rese-cel (resecabtagene autoleucel), is a fully human CD19-CAR T cell therapy evaluated through the RESET clinical development program across rheumatology, neurology and dermatology.
Recurring company updates cover rese-cel clinical and translational data, trial-program presentations, manufacturing scale-up, and supply arrangements using automated cell-therapy production platforms. News also includes financial results, business updates, conference participation, shareholder voting matters, capital-structure disclosures, and regulatory disclosures tied to Cabaletta Bio’s autoimmune cell-therapy pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.